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A Senescence Program Controlled
by p53 and p16INK4a Contributes
to the Outcome of Cancer Therapy
through common pathways and, consequently, muta-
tions that disable these pathways can confer multidrug
resistance (Lowe et al., 1993). For example, the Bcl2
oncoprotein is a potent suppressor of apoptosis that
can produce multidrug resistance in cultured cells and
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clinical drug resistance has been difficult to assess.
Many of the genes that control apoptosis during tumor
development can also influence treatment sensitivity.Summary
For example, the p53 tumor suppressor promotes apo-
ptosis in response to stress-inducing stimuli, and, inp53 and INK4a/ARF mutations promote tumorigenesis
turn, p53 inactivation facilitates tumor development (Vo-and drug resistance, in part, by disabling apoptosis.
gelstein et al., 2000). Anticancer agents also activateWe show that primary murine lymphomas also re-
p53 to promote apoptosis, and loss of p53 function canspond to chemotherapy by engaging a senescence
promote drug resistance in cultured cells and animalprogram controlled by p53 and p16INK4a. Hence, tumors
models (e.g., Lowe et al., 1993; Schmitt et al., 1999).with p53 or INK4a/ARF mutations—but not those lack-
Hence, p53 mutations can simultaneously account foring ARF alone—respond poorly to cyclophosphamide
a survival advantage during tumor development and in-therapy in vivo. Moreover, tumors harboring a Bcl2-
herent resistance to chemotherapeutic drugs. Of note,mediated apoptotic block undergo a drug-induced cy-
p53 can also engage several cell-cycle checkpoints andtostasis involving the accumulation of p53, p16INK4a,
trigger cellular senescence (Bunz et al., 1998; Chang etand senescence markers, and typically acquire p53 or
al., 1999; Kastan et al., 1991; Suzuki et al., 2001; Wald-INK4a mutations upon progression to a terminal stage.
man et al., 1997), although the extent to which theseFinally, mice bearing tumors capable of drug-induced
processes contribute to drug action in vivo is not known.senescence have a much better prognosis following
Like p53, the INK4a/ARF locus is frequently mutatedchemotherapy than those harboring tumors with se-
in human cancers and has been linked to treatmentnescence defects. Therefore, cellular senescence con-
sensitivity. This locus encodes two tumor suppressors—tributes to treatment outcome in vivo.
ARF and p16INK4a—that share coding sequence trans-
lated in different reading frames (Sherr, 2001a). ARF can
Introduction activate p53 by interfering with its negative regulator
Mdm2. Most studies show that ARF is not induced by
Chemotherapy remains the primary treatment for sys- DNA damage but can potentiate a DNA damage re-
temic malignancies. However, some tumors are inher- sponse (de Stanchina et al., 1998; Kamijo et al., 1999).
ently insensitive to chemotherapeutic agents and others Instead, ARF is induced by mitogenic oncogenes, per-
acquire resistance upon relapse. Most conventional haps as part of a failsafe mechanism that counters
agents damage cellular components, often DNA, and hyperproliferative signals (Sherr, 2001a). By contrast,
for years it was assumed that this damage was directly p16INK4a is a cyclin-dependent kinase inhibitor that pro-
responsible for their anti-tumor effect (Johnstone et al., motes cell-cycle arrest via the Rb tumor suppressor
2002). Consequently, drug resistance was thought to pathway. INK4a regulation is poorly understood, but its
arise primarily from changes that prevented the drug- expression increases with the onset of cellular senes-
target interaction, including overexpression of drug ef- cence (Alcorta et al., 1996; Hara et al., 1996; Robles and
flux pumps (e.g., P-glycoprotein) or intracellular detoxifi- Adami, 1998; Serrano et al., 1997). Mutations affecting
ers (e.g., glutathione). It is now clear that drug-induced both INK4a and ARF are common in malignant tumors,
damage is not invariably lethal, but can instead initiate although disruption of either gene alone promotes tu-
a series of post-damage responses including apoptosis, morigenesis in mice and humans (Ruas and Peters,
cell-cycle checkpoints, mitotic catastrophe, and cellular 1998; Sherr, 2001b). INK4a/ARF deletions correlate with
senescence (Chang et al., 1999; Johnstone et al., 2002). poor treatment outcome in patients and in mouse mod-
Accordingly, the integrity of these damage responses els (Maloney et al., 1999; Schmitt et al., 1999), although
might also influence treatment sensitivity. the precise contribution of each gene product to treat-
ment sensitivity has not been examined.Apoptosis is a well-characterized post-damage pro-
The determinants of drug action are typically studiedgram that contributes to drug action (Johnstone et al.,
in tumor-derived cell lines treated in culture or as xeno-2002). Diverse anticancer agents can induce apoptosis
grafts. Animal models that recapitulate the genetics and
pathobiology of human malignancies provide powerful3 Correspondence: lowe@cshl.edu
alternatives, since these systems are experimentally4 Present address: Max-Delbru¨ck-Center for Molecular Medicine and
tractable yet utilize spontaneous tumors treated at theirCharite´/Campus Virchow-Hospital, Department of Hematology/On-
cology, Humboldt University, D-13353 Berlin, Germany. natural site. E-myc transgenic mice overexpress the
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Table 1. Designation of Lymphomas With Defined Genetic Lesions (in bold)
Infection of established lymphomasc Infection of hematopoietic stem cellsc
(lymphomas develop in the absence (lymphomas develop in the presence
Normal cell genotypea,b Retroviral construct of the transduced gene) of the transduced gene)




myc tsg/ no tsg/ or tsg-null tsg/HSC or tsg-nullHSC
MSCV tsg/-MSCV or tsg-null-MSCV tsg/HSC-MSCV or tsg-nullHSC-MSCV
MSCV-bcl2 tsg/-bcl2 or tsg-null-bcl2 tsg/HSC-bcl2 or tsg-nullHSC-bcl2
MSCV-C9DN tsg/-C9DN or tsg-null-C9DN tsg/HSC-C9DN or tsg-nullHSC-C9DN
atsg (tumor suppressor gene), such as p53, ARF, or INK4a/ARF.
b Lymphomas arising from / cells (no targeted gene deletion) form as “controls” (ctrl.).
c Lymphomas arising from / cells not preserving a functional wild-type sequence—at the time of tumor establishment or after therapy—are
considered “null.”
c-myc oncogene in the B-cell lineage (Adams et al., temic lymphomas in which only malignant cells were
fluorescent.1985), and the resulting B-cell malignancies resemble hu-
man non-Hodgkin’s lymphomas. We previously devel- Previous studies have shown that GFP can be visual-
ized in tumor xenografts by whole-body fluorescenceoped methods for rapidly producing E-myc lymphomas
with compound genetic lesions, as well as strategies imaging (Yang et al., 2000). Here, manifestations of GFP-
tagged E-myc lymphomas were readily visualized infor studying treatment responses that parallel clinical
trials (Schmitt et al., 1999, 2000b, 2002). As in human the lymph nodes (LN), bone, and other organs of recipi-
ent mice—precisely matching the anatomical locationscancers, mutations that disrupt p53 or the INK4a/ARF
locus compromise therapy in E-myc lymphomas predicted from pathological evaluation (Figure 1A). Lym-
phoma-bearing mice were treated with cyclophospha-(Schmitt et al., 1999). Therefore, using this system, the
biologic and genetic determinants of drug action can mide (CTX), an alkylating agent that is used against
lymphomas and other malignancies. Ctrl.-MSCV tumorsbe studied in a relevant setting, yet in a manner not
possible in patients. Here, we use the E-myc model to typically responded rapidly to CTX, with no GFP fluores-
cence detectable by 24 hr or thereafter (Figure 1A). Inexplore the biologic and genetic basis for drug action
and drug resistance, and find that a senescence pro- contrast, p53 null-MSCV tumors underwent a delayed
response, and invariably relapsed (Figure 1A). Remark-gram controlled by p53 and p16INK4a is an important deter-
minant of treatment outcome in vivo. ably, ctrl.-bcl2-transduced tumors displayed virtually no
response to CTX, even though it was administered at
the maximum tolerated dose. The initial response ofResults
these tumors parallels what has been observed in mouse
cohorts (Schmitt et al., 1999, 2000b), and indicates thatNonapoptotic Functions of p53 Contribute
to Treatment Outcome CTX action engages both p53-dependent and indepen-
dent apoptotic programs.The ability of p53 to induce apoptosis in response to
DNA damage is considered an important determinant Although the ctrl.-bcl2 tumors failed to regress follow-
ing therapy, they did not progress for extended periodsof drug action. Concordantly, both loss of p53 and over-
expression of Bcl2 (which acts downstream of p53 to (Figure 1A). This is in marked contrast to p53 null-MSCV
and p53 null-bcl2 tumors, which progressed rapidly (Fig-suppress apoptosis) compromise therapy in E-myc
lymphomas (Schmitt et al., 1999, 2000b). To compare ure 1A, and data not shown). To extend these results, we
compared the tumor-free survival (i.e., time-to-relapse)and contrast the impact of these lesions on treatment
sensitivity, we generated a panel of primary lymphomas and overall survival of CTX-treated mice harboring tu-
mors lacking p53 or overexpressing Bcl2. As expected,with defined genetic lesions (Schmitt et al., 2000b). We
introduced retroviral vectors expressing green fluores- both lesions prevented mice from achieving long-lasting
remissions (Figure 1B; compare to ctrl.-MSCV). How-cent protein (GFP) alone (MSCV), or coexpressing Bcl2
and GFP (MSCV-bcl2), into primary E-myc lymphomas ever, mice harboring ctrl.-bcl2 lymphomas lived much
longer than mice with p53 null lymphomas (Figure 1B;arising in control (ctrl.) or p53/ animals. Note that lym-
phomas arising in p53/ mice invariably lose the wild- p  0.0001, e.g., at 30 days: 75% overall survival for
ctrl.-bcl2 versus 0% for both p53 null groups). Bcl2 didtype p53 allele and become p53 null. This procedure
produced four lymphoma populations, designated as not affect overall survival in the p53 null group, implying
that neither its potential role in delaying cell-cycle entryctrl.-MSCV, ctrl.-bcl2, p53 null-MSCV, and p53 null-bcl2,
respectively (Table 1). Retrovirally transduced cells were nor its impact on p53-independent apoptosis alters out-
come in this model. Still, unlike the ctrl.-MSCV group,immediately injected into tail veins of syngeneic recipi-
ent mice, where the transplanted GFP-tagged lym- all mice harboring ctrl.-bcl2 lymphomas eventually suc-
cumbed to their disease (Figure 1B; p  0.0061; 50%phoma cells establish tumors histopathologically indis-
tinguishable from the primary malignancies (Schmitt et versus 0% overall survival at day 100, respectively).
Therefore, the initial response to CTX does not neces-al., 1999, 2000b). Thus, recipient animals developed sys-
Drug-Induced Senescence In Vivo
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Figure 1. Contribution of p53 and Bcl2 to Treatment Responses
(A) Mice harboring ctrl.-MSCV, p53 null-MSCV, and ctrl.-bcl2 lymphomas were treated at comparable tumor burdens (day 0) with a single
dose of cyclophosphamide (CTX) and monitored by whole-body fluorescence imaging. Representative examples are shown.
(B) Kaplan-Meier plots for tumor-free survival (left) and overall survival (right) following CTX therapy. Curves reflect the response of ctrl.-MSCV
(black, n  13), ctrl.-bcl2 (dark green, n  23), p53 null-MSCV (red, n  7), and p53 null-bcl2 (purple, n  11). The mice monitored for disease-
free survival are the same as those evaluated for overall survival.
sarily predict treatment outcome. The fact that Bcl2 mice, where they rapidly formed aggressive lymphomas
(ctrl.HSC-bcl2, Table 1) (Schmitt et al., 2002). Importantly,does not recapitulate the impact of p53 loss on overall
survival implies that nonapoptotic p53 functions are im- apoptosis is the only p53 effector function that sup-
presses myc-driven lymphomagenesis, so these Bcl2portant in treatment sensitivity.
expressing lymphomas preserve an intact p53 pathway
(Schmitt et al., 2002). Retransplantation of the ctrl.HSC-CTX Induces a p53-Dependent Cell-Cycle
Arrest In Vivo bcl2 lymphomas into several recipients each allowed us
to examine the same lymphoma in the presence andThe fact that ctrl.-bcl2 tumors remain viable but static
for extended periods suggests that CTX can engage a absence of CTX therapy. Such tumors are comparable,
since the response of the same tumor treated in twop53-dependent cell-cycle arrest program. Therefore, we
measured cell proliferation and p53 expression in CTX- different mice is similar (Schmitt and Lowe, 2001).
Upon manifestation of transplanted tumors, LNs weretreated lymphomas overexpressing Bcl2. Of note, a sub-
set of lymphomas arising in E-myc transgenic mice either harvested directly (untreated) or 7 days after CTX
treatment. Cell proliferation was estimated by countingacquires spontaneous mutations in the p53 pathway,
which produces a heterogeneous cohort of ctrl. lympho- mitotic figures, measuring the in vivo incorporation of
5-bromo-2-deoxyuridine (BrdU), or by staining with themas with and without functional p53 (Eischen et al.,
1999). To circumvent this problem, MSCV-bcl2-trans- proliferation marker Ki-67. In contrast to untreated lym-
phomas, CTX-treated tumors completely lacked mitoticduced hematopoietic stem cells (HSC; derived from E-
myc transgenic fetal livers) were used to reconstitute figures and were BrdU and Ki67 negative (Figure 2A).
Moreover, ctrl.HSC-bcl2 tumors displayed sustained in-the hematopoietic system of lethally irradiated recipient
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lymphomagenesis (Schmitt et al., 2002). Consequently,
these tumors remained p53/, even upon transplanta-
tion into recipient mice (Figure 2C, lane 1, 4/4 tested).
However, neither gene prevented p53 loss during ther-
apy, since most of these lymphomas became p53 null
after two administrations of CTX (2/5 for p53/HSC-bcl2,
Figure 2C; 2/2 for p53/HSC-C9DN, data not shown). Con-
cordantly, p53 null lymphomas—irrespective of their Bcl2
status—did not arrest following CTX therapy (data not
shown). Therefore, disruption of a p53-dependent arrest
program promotes treatment failure.
Contribution of the INK4a/ARF Locus to Tumor
Onset and Treatment Outcome
We gained further insights into the determinants of drug
action by studying the INK4a/ARF locus during tumor
development and therapy. Tumors of different geno-
types were generated by intercrossing E-myc trans-
genic animals to either p53/, ARF/ mice (targeting
exon 1), or INK4a/ARF/ (targeting exons 2 and 3),
all in the C57BL/6 genetic background (see Figure 3A).
Consistent with results from mixed backgrounds
(Schmitt et al., 1999), tumors arising in each mutant
arose with a similar latency yet much more rapidly than
controls (p  0.0001, median onset: 32, 34, and 47 days
for p53/, INK4a/ARF/, and ARF/ animals, respec-
tively; compare to 139 days for E-myc controls; see
Supplemental Data available online at http://www.cell.
com/cgi/content/full/109/3/335/DC1). Importantly, al-
most all tumors arising in p53/ and INK4a/ARF/ ani-
mals lost the wild-type allele and became p53 or INK4a/
ARF null, respectively (Figure 3A and Schmitt et al.,
1999). None of the lymphomas arising in the ARF/
background expressed detectable protein (Figure 3A;Figure 2. Role of p53 in Drug-Induced Arrest
17/17 tested, hereafter designated ARF null), whereas(A) Ctrl.HSC-bcl2 lymphomas were transplanted into several recipients
only 65% showed loss of exon 1 (ARF null	1; seeeach. Upon tumor formation, parallel tumors originating from the
also Eischen et al., 1999). Interestingly, Southern blotssame initial lymphoma were resected from either untreated animals
or 7 days post-CTX therapy. Lymph-node sections were stained using an exon-2-specific probe suggested that those
with hematoxylin-eosin (H/E [top]; high power field; arrows point to ARF null tumors in which exon 1 was retained (ARF
mitotic figures) or underwent immunostaining using anti-BrdU or null1) had heterozygous deletions encompassing exonanti-Ki67 antibodies (representative medium power fields are
2 (Figure 3A, p  0.05). TUNEL analysis of LN sectionsshown).
revealed that p53 null, INK4a/ARF null and ARF null(B) p53 immunoblot analysis in ctrl.HSC-bcl2 lymphomas of samples
lymphomas were less prone to spontaneous apoptosis,described in (A). 
-Tubulin (Tub) is used as a loading control.
(C) p53/HSC-bcl2 lymphomas were tested for p53 gene status fol- suggesting that loss of apoptosis contributed to rapid
lowing two administrations of CTX. The persistence of the mutant lymphoma onset (Supplemental Data at above URL). In
(mut) and wild-type (wt) alleles was determined by allele-specific contrast, disruption of Rb or INK4a alone had no impact
PCR on tumor DNA. Shown are one representative untreated (ut)
on the onset of E-myc lymphomas (Krimpenfort et al.,and 4 CTX-treated samples.
2001; Schmitt et al., 1999). Consequently, ARF is the
sole product of the INK4a/ARF locus that suppresses
myc-induced lymphomagenesis.
INK4a/ARF mutations can compromise therapy in E-creases in p53 expression post-therapy (Figure 2B).
Therefore, CTX is cytostatic to p53-expressing tumors myc lymphomas (Schmitt et al., 1999). Since loss of ARF
disables p53 during lymphomagenesis and ARF can po-that are insensitive to apoptosis.
If p53 contributes to a prognostically significant arrest tentiate DNA damage responses (de Stanchina et al.,
1998; Kamijo et al., 1999; Schmitt et al., 1999), we ex-program following CTX therapy, then p53 mutations
should confer a selective advantage to tumor cells dur- pected treatment responses of ARF null and INK4a/
ARF null lymphomas to be similar. Lymphomas of theing therapy, even in the presence of an apoptotic block.
Therefore, we introduced MSCV-bcl2 or a dominant- genotypes described above were propagated in synge-
neic recipients and treated with CTX upon tumor mani-negative caspase 9 (MSCV-C9DN) into p53/ E-myc
transgenic fetal liver cells, and allowed lymphomas to festation. To our surprise, the ARF null and INK4a/ARF
null lymphomas behaved differently: the ARF null groupform in recipient mice (p53/HSC-bcl2 or p53/HSC-C9DN,
respectively). Both genes block apoptosis downstream responded much better than the INK4a/ARF null group
(Figure 3B, p  0.002), with tumor-free survival ratesof p53, and are sufficient to prevent p53 loss during
Drug-Induced Senescence In Vivo
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Figure 3. The INK4a/ARF Locus in Tumor Development and Treatment Responses
(A) Allelic losses in lymphomas arising in either INK4a/ARF/ or ARF/ genetic backgrounds are illustrated schematically. Greater than 90%
of the INK4a/ARF/ derived lymphomas inactivate in 90% both gene products by deletions involving exon 2 (28/31 cases; data not shown).
By contrast, only 65% of ARF/ derived lymphomas (13/20 tested) lost exon 1 (ARF null	1; data not shown). Those that retained exon 1
(ARF null1, 7/20 tested) may disrupt ARF through loss of exon 2 instead, thereby creating INK4a heterozygosity. Concordantly, no ARF
protein was detected by immunoblotting in any of the ARF/ lymphomas tested (17/17, examples for ARF null1 [a, b] and for ARF null	1
[c, d] are shown along with p53/ and INK4a/ARF/ MEFs and p53 null, ctrl., and INK4a/ARF null lymphomas for comparison), and Southern
blot analysis revealed an almost 50% reduction of exon 2 copy number for ARF null1 lymphomas relative to ARF null	1 lymphomas (n  5
each; mean signal intensity  SD).
(B) Tumor-free survival following CTX treatment of mice harboring ctrl. (black, n  58), p53 null (red, n  24), ARF null (green, n  26) or
INK4a/ARF null (blue, n  35) lymphomas. The ctrl., p53 null, and INK4a/ARF null curves incorporate some data previously published (Schmitt
et al., 1999).
(C) Tumor-free survival (left) and overall survival (right) in mouse cohorts harboring ARF null-MSCV (green, n  9), ARF null-bcl2 (dark green,
n  8), INK4a/ARF null-MSCV (blue, n  9), and INK4a/ARF null-bcl2 (purple, n  12) lymphomas.
similar to those of ctrl. lymphoma bearing mice. There- 60% surviving at 50 days post-therapy, respectively).
Interestingly, whereas Bcl2 had no impact on overallfore, INK4a mutations apparently compromise treat-
ment outcome. survival in the p53 null group, it reduced overall survival
in the INK4a/ARF null setting (p  0.0007). In fact, theWe next examined the impact of ARF or INK4a/ARF
deletions on tumor-free and overall survival following overall survival of the INK4/ARF null-bcl2 group ap-
proached that of both p53 null groups (Figure 3C; com-CTX therapy in the presence and absence of Bcl2 (Figure
3C). The overall survival of mice bearing ARF null-MSCV pare to Figure 1B). This suggests that INK4a loss and
disruption of apoptosis by Bcl2 act independently totumors was similar to controls (compare to ctrl.-MSCV
in Figure 1B), and superior to mice bearing p53 null- promote drug resistance.
MSCV lymphomas (p  0.0025; compare to Figure 1B).
In contrast, mice harboring INK4/ARF null-MSCV lym- Selection Against INK4a Genes In Vivo
The above experiments describe how engineered dele-phomas rapidly progressed to a terminal stage (p 
0.0278 for overall survival of ctrl.-MSCV [Figure 1B] ver- tions at the INK4a/ARF locus affect treatment outcome.
Spontaneous mutations also occur at this locus, andsus INK4/ARF null-MSCV [Figure 3C]). Consequently,
the INK4a/ARF null group had a much worse prognosis their association with poor outcome provides additional
evidence that the INK4a status influences treatment sen-than the ARF null group ([Figure 3C], 10% versus
Cell
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sitivity. For example, E-myc lymphomas can acquire
homozygous deletions of the INK4a/ARF locus (Eischen
et al., 1999), and these lesions can be detected by multi-
plex PCR analysis of genomic DNA using exon-specific
primers (see schematic diagram in Figure 3A). Biallelic
loss restricted to exon 1
 was never observed, and
losses restricted to exon 1 (the ARF exclusive first
exon) were extremely rare (1/52 cases). However, homo-
zygous deletions involving exon 2 were relatively com-
mon, occurring in 27% (14/52) of the cases (data not
shown). When the CTX response of ctrl. lymphomas was
stratified based on their exon 2 status, those with a
homozygous deletion of exon 2 responded poorly (p 
0.016), much like the INK4a/ARF null group (Figure 4A,
compare to 3B).
The response of ARF null tumors could be further
stratified based on the pretreatment status of exon 1
(Figure 4A). As shown above, ARF null lymphomas can
arise with (ARF null1) or without (ARF null	1) exon 1
genomic sequences. Remarkably, mice harboring ARF
null1 tumors responded as poorly as those bearing
lymphomas with engineered or spontaneous INK4a/ARF
deletions (Figure 4A, see also Figure 3B). Moreover, mul-
tiplex PCR analysis of lymphoma DNA isolated after two
rounds of CTX therapy revealed that the majority had
completely lost exon 2 (4 of 6 tested, Figure 4B, compare
lane 2 to 3). Therefore, INK4a deletions provide a selec-
tive advantage to tumor cells during chemotherapy. That
most ARF null1 lymphomas lost one copy of exon 2
during tumor development may have predisposed these
tumors to loss of the other allele during CTX therapy
(see Figure 3A).
By contrast, mice harboring ARF null	1 lymphomas
displayed a superb prognosis (p  0.046, compared to
ARF null1), even superior to ctrls. (Figure 4A). One
explanation for this is that ctrl. lymphomas comprise a
heterogeneous group, including subsets acquiring
INK4a/ARF deletions or p53 mutations (Eischen et al.,
1999; Schmitt et al., 1999) that negatively bias their over-
all response. However, the ARF null group never con-Figure 4. Spontaneous Mutations at the INK4a/ARF Locus and Anti-
tained tumors with p53 mutations (Eischen et al., 1999),cancer Therapy
and our data imply that those also retaining intact INK4a(A) Tumor-free survival for ctrl. and ARF null lymphomas after CTX
genes are invariably cured by CTX therapy. Indeed, onetherapy stratified by the INK4a/ARF gene status prior to treatment
as determined by exon-specific PCR. Compare ctrl. lymphomas of the two relapses occurring in the ARF null	1 subgroup
with a detectable exon 2 (exon 2, black, n  23) to those with a displayed a homozygous deletion encompassing INK4a
homozygous deletion in exon 2 (	exon 2, blue, n  7). Compare exon 2 (data not shown). Consequently, the majority of
ARF null1 lymphomas (light green, n 6) to ARF null	1 lymphomas the relapses (5/7 tested) in the ARF null group could be
(gray, n  11).
linked to either a CTX-induced INK4a deletion or an(B) Multiplex PCR analysis of genomic DNA isolated from the same
INK4a/ARF codeletion.lymphomas left untreated (ut) or isolated after two rounds of CTX
p53 mutations confer an advantage to tumor cellstherapy. A representative ARF null sample is shown, with a ctrl. and
INK4a/ARF null sample for comparison. 
-actin is a PCR control. during CTX therapy, even when apoptosis is efficiently
Treated ARF null lymphomas showed exon 2 deletions in 5 of 7 blocked (see Figure 2). To determine whether this is also
cases tested. true for the INK4a/ARF mutations, we transduced E-
(C) Left: Primary INK4a/ARF/HSC-MSCV and INK4a/ARF/HSC-bcl2 myc INK4a/ARF/ hematopoietic stem cells with eitherlymphomas were isolated and a portion transplanted into syngeneic
MSCV or MSCV-bcl2, and allowed lymphomas to formrecipients for subsequent analysis of INK4a/ARF status before and
in recipient mice. MSCV-transduced lymphomas lost theafter CTX therapy. Shown is a multiplex PCR analysis of genomic
DNA from the primary lymphomas or from the transplanted INK4a/ wild-type INK4a/ARF allele during lymphoma expansion
ARF/HSC-bcl2 lymphomas either left untreated (ut) or following re- whereas the MSCV-bcl2 transduced lymphomas did not
lapse after repeated CTX treatments. 
-actin and neomycin (neo) (Figure 4C, compare lanes 1 and 2). This demonstrates
were included as PCR controls. Right: Aliquots of a primary ARF that disruption of apoptosis can substitute for INK4a/null lymphoma were transduced with either MSCV-bcl2 or MSCV-
ARF loss during lymphomagenesis, and provides addi-p16as and transplanted into recipient mice. Shown is a multiplex
tional evidence that the cell-cycle inhibitor p16INK4a doesPCR analysis of genomic DNA isolated from lymphomas left un-
treated or upon relapse following CTX therapy. A similar result was not contribute to tumor suppression in this setting (Krim-
obtained using another primary ARF null lymphoma. penfort et al., 2001). INK4a/ARF/HSC-bcl2 cells were
Drug-Induced Senescence In Vivo
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Figure 5. p16INK4a Expression in CTX-Treated
Lymphomas Overexpressing Bcl2
(A) Ctrl.HSC-bcl2 lymphomas were retrans-
planted into several recipients and harvested
either untreated (ut) or seven days after CTX
therapy (7d CTX; as in Figure 2). p16INK4a pro-
tein was detected by immunoblotting. p53
null-bcl2 and ARF null-bcl2 samples are
shown for comparison, and wild-type (wt),
INK4a/ARF/ MEF serve as controls. Shown
is a short exposure to visualize p16INK4a induc-
ibility in p53-deficient cells (left). Expression
of tubulin (Tub) is shown as a loading control.
Note that the ARF null-bcl2 samples are not
the same blot or exposure as the ctrlHSC-bcl2
lymphomas. In a different ctrl.HSC-bcl2 lym-
phoma pair, p16INK4a protein levels were de-
tected by anti-p16INK4a immunoprecipitation
(IP) preceding immunoblotting (right).
(B) p16INK4a immunohistochemistry (IHC) in a
representative ctrl.HSC-bcl2 lymphoma sam-
ple generated as in (A), (medium power field;
high power inlay shows nuclear reactivity).
then injected into syngeneic recipients, and the lym- 5B). Importantly, ARF was not required for p16INK4a induc-
tion, since CTX also induced p16INK4a in ARF null lympho-phoma-bearing mice were either left untreated (ut) or
were treated with CTX. Whereas the untreated lympho- mas expressing Bcl2 (Figure 5A). Paradoxically, p16INK4a
levels were extremely high in p53 null lymphomas over-mas retained exon 2, the CTX-treated tumors did not
(Figure 4C, compare lanes 3 and 4). Therefore, the expressing Bcl2, and these levels further increased in
response to CTX (Figure 5A). Thus, p16INK4a is activatedINK4a/ARF locus encodes a nonapoptotic activity that
contributes to treatment sensitivity. in response to CTX where, in the presence of p53, it
potentiates treatment sensitivity.To further evaluate the impact of INK4a status on
treatment responses, ARF null1 lymphomas were
transduced with MSCV-bcl2 or MSCV-p16as, an INK4a- Cooperation between p16INK4a and p53
exon1
-specific antisense construct that effectively The fact that p53 null lymphomas express high p16INK4a
suppresses INK4a expression (Carnero et al., 2000) (see levels but proliferate suggests that p53 might contribute
Supplemental Data). The transduced cells were trans- to p16INK4a action. To test this directly, we reintroduced
planted into several recipient animals each, and the re- cDNAs encoding ARF or p16INK4a (MSCV-ARF and MSCV-
sulting lymphomas were either harvested directly or p16, respectively) into INK4a/ARF null or p53 null lym-
after two rounds of CTX therapy. Multiplex PCR analysis phomas by retroviral transduction. The coexpressed
revealed that exon 2 was retained in untreated ARF GFP was monitored by flow cytometry to identify the
null-bcl2 lymphomas but lost upon relapse (Figure 4C, fraction of cells expressing ARF or p16INK4a (Figure 6A),
compare lane 5 to 6). In contrast, exon 2 was retained and proper protein expression was confirmed by immu-
in ARF null tumors expressing MSCV-p16as, even after noblotting (data not shown). Neither ARF nor p16INK4a
CTX therapy (lane 7). Taken together, our data demon- could be efficiently expressed in INK4a/ARF null lym-
strate that mutations targeting INK4a produce a selec- phomas 48 hr after infection (Figures 6A and 6B). How-
tive advantage during therapy, thereby contributing to ever, consistent with ARF acting upstream of p53, a
both intrinsic and acquired drug resistance. substantial fraction of p53 null lymphoma cells ex-
pressed MSCV-ARF. Surprisingly, p53 null cells also tol-
erated MSCV-p16 expression, suggesting that p53 lossp16INK4a Is Activated Following Drug Treatment
In Vivo reduces selective pressure to eliminate INK4a. The fact
that high p16INK4a levels—as occur following CTX treat-The data described above demonstrate that INK4a gene
status is an important determinant of treatment outcome ment—are inhibitory to INK4a/ARF null cells but not p53
null cells places p16INK4a either upstream of p53 or in ain vivo. Interestingly, p16INK4a acts strictly to promote cell-
cycle arrest (Sherr, 2001a), and its expression increases parallel pathway.
To further delineate the relationship between p53 andwith delayed kinetics following DNA damage in vitro
(Robles and Adami, 1998; Suzuki et al., 2001) To de- p16INK4a in treatment responses, we asked whether p53
inactivation would alleviate pressure to mutate INK4a/termine whether p16INK4a responds to drug treatment
in vivo, p16INK4a levels were examined in transplanted ARF during CTX therapy, and vice versa. Indeed, p53
null;INK4a/ARF/ lymphomas (generated by intercross-ctrl.HSC-bcl2 lymphomas before and after CTX therapy.
As was observed for p53 (see Figure 2B), p16INK4a levels ing [Schmitt et al., 1999]) never displayed a treatment-
induced loss of the remaining INK4a/ARF allele (0/5increased markedly by 7 days post-treatment. This in-
crease was observed by immunoblotting with or without tested; Figure 6C). Conversely, p53 was never mutated
in INK4a/ARF null lymphomas that received multipleprior anti-p16INK4a immunoprecipitation (Figure 5A), and
by immunohistochemical staining of LN sections (Figure rounds of CTX (0/6 tested). Hence, p53 and p16INK4a co-
Cell
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Figure 6. Cooperation Between p16INK4a and
p53
(A) Primary lymphomas were infected with
MSCV, MSCV-ARF or MSCV-p16 which each
co-encode GFP on a bicistronic message,
thus allowing measurement of the fraction of
infected cells by fluorescence. 48 hr after in-
fection, cells were subjected to flow cytome-
try to determine the percentage of GFP posi-
tive cells.
(B) Quantification of data in (A). Data are plot-
ted relative to the infection efficiency using
MSCV (n  4 for INK4a/ARF null and n  2
for p53 null lymphomas. Data represent the
mean  SD.
(C) Multiplex PCR analysis of p53 null;INK4a/
ARF/ lymphomas following two rounds of
CTX therapy. These lymphomas never lost
the remaining INK4a/ARF allele (shown are 4/5
cases tested, and an INK4a/ARF null lym-
phoma as a control). Conversely, no p53 mu-
tations were detected by RT-PCR sequenc-
ing in repeatedly CTX-treated INK4a/ARF null
lymphomas (data not shown).
operate during treatment responses, apparently by en- els within 7 days (Figure 7A). These tumors also upregu-
lated PML, an independent senescence marker (data notgaging a program of prolonged cell-cycle arrest.
shown). In contrast, p53 null-bcl2 lymphomas remained
negative for SA--gal activity. Also, ARF null-bcl2 (Fig-Chemotherapy Induces Premature Senescence
In Vivo ure 5A) accumulated SA--gal activity in response to
CTX, whereas INK4a/ARF null-bcl2 lymphomas did notThe cytostasis provoked by CTX is reminiscent of cellu-
lar senescence. This program, initially linked to the repli- (Figure 7B). Hence, loss of either p53 or INK4a genes
disabled premature senescence provoked by CTX.cative aging of human fibroblasts in culture (Hayflick
and Moorhead, 1961), is considered permanent and is These findings demonstrate that the outcome of cancer
therapy can be linked to a drug-inducible senescencecharacterized by specific changes including upregula-
tion or the PML gene product, and the accumulation program controlled by p53 and p16INK4a.
of a senescence-associated -galactosidase (SA--gal)
activity (Campisi, 2001). Although “replicative” senes- Discussion
cence is triggered by telomere malfunction, a similar
endpoint can be produced acutely in response to acti- Cyclophosphamide has been successfully used to treat
many human malignancies. Although CTX is not subjectvated oncogenes, oxidative stress, radiation, and cer-
tain chemotherapeutic drugs (Chang et al., 1999; Di Leo- to resistance mechanisms involving enhanced drug ef-
flux, many human tumors respond poorly or becomenardo et al., 1994; Serrano et al., 1997). Whether cellular
senescence occurs in vivo is controversial, but SA- resistant to this agent. We used a unique murine lym-
phoma model to show that the anti-tumor activity of-gal-positive cells accumulate in older individuals (Di-
mri et al., 1995). Most importantly, however, the program CTX depends on its ability to induce both apoptosis
and senescence. Tumors lacking both programs rapidlyis controlled by the p53 and p16/Rb tumor suppressor
pathways (Campisi, 2001). progress to a lethal stage, suggesting that post-damage
responses are almost completely responsible for CTXTo determine whether CTX-induced cytostasis has
features of cellular senescence, we examined SA--gal action. Together, our results establish a paradigm for
understanding drug action, as well as the interconnec-activity in ctrl.HSC-bcl2 lymphomas. These lymphomas
were chosen because they respond to CTX by a cell- tions between tumorigenesis and drug resistance. This
paradigm will undoubtedly apply to other conventionalcycle arrest involving p53 and p16INK4a (see above). Indi-
vidual samples were transplanted into several recipients anticancer agents, and perhaps many “targeted thera-
peutics.”each, and SA--gal activity was examined in lymphoma
sections at various times post-treatment. SA--gal ac-
tivity was not detected in untreated lymphomas, but Senescence Contributes to Treatment Outcome
Our study provides direct evidence that cellular senes-progressively accumulated between 1 and 2 days post-
therapy (data not shown), achieving extremely high lev- cence can be induced following chemotherapy in vivo,
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leading to an anti-tumor effect. In fibroblasts and epithe-
lial cells, senescence is controlled by the p53 and Rb
tumor suppressor pathways, although the contribution
of each pathway to the program depends on species
and cell type (e.g., Randle et al., 2001). Cell-cycle arrest
is considered permanent, and is accompanied by
changes in gene expression and upregulation of SA-
-gal activity. Here, drug-induced arrest was accompa-
nied by substantial increases in p53, p16INK4a (an Rb
regulator linked exclusively to senescence), PML, and
SA--gal activity (Figures 2, 5, and 7). Disruption of either
p53 or INK4a disabled the arrest program, prevented
SA--gal accumulation, and acquired loss of either gene
often accompanied progression of once dormant tu-
mors to a terminal stage (Figures 2, 5, and 7). The latter
observation is consistent with the possibility that CTX-
induced cytostasis is stable, and its escape requires
rare pre-existing mutations that disable the program.
Importantly, the senescence program contributed to
treatment outcome, since mice harboring tumors capa-
ble of senescence but not apoptosis had a substantially
better post-therapy prognosis than those harboring tu-
mors with defects in both processes (Figures 1 and 3).
Cellular senescence may parallel apoptosis as a
global response to stress. Indeed, we see that both
apoptosis and senescence contribute to drug action,
and that loss of either process promotes treatment fail-
ure. Interestingly, certain agents that trigger apoptosis
in one cell type induce senescence in another, and p53
and the INK4a/ARF locus encode important regulators
of both processes. Why some cells undergo apoptosis
while others senesce is not known, but we note that
drug-induced senescence is most pronounced in the
presence of an apoptotic block. This suggests that se-
nescence can serve as a “backup” to apoptosis, and
may explain the inability of Bcl2 to enhance clonogenic
survival following drug treatment in vitro (Brown and
Wouters, 1999). This backup may be particularly impor-
tant in cell types not naturally prone to apoptosis or in
solid cancers that have acquired an apoptotic block
during the course of tumor evolution.
p53 Action in Mediating Treatment Responses
Figure 7. Cellular Senescence and Cancer Therapy In Vivo Our results clarify the relationship between p53 and
(A) Matched pairs (untreated versus seven days post CTX therapy) treatment sensitivity. Anticancer agents can activate
of ctrl.HSC-bcl2 and p53 null-bcl2 lymphoma sections were compared p53 to promote apoptosis, implying that apoptotic de-
for senescence-associated -galactosidase (SA--gal) activity in
fects contribute to the poor outcome of patients harbor-situ (low power field).
ing p53 mutant tumors. However, these results do not(B) Detection of SA--gal activity in matched pairs of untreated
preclude the possibility that additional p53 activitiesversus CTX-treated ARF null-bcl2 and INK4/ARF null-bcl2 lympho-
mas in situ. As in (A), experiments were conducted at least in dupli- contribute to drug action. Indeed, ctrl. lymphomas in
cate using separate primary lymphomas. which apoptosis is disrupted downstream of p53 re-
(C) Model of therapy-induced senescence controlled by p16INK4a and spond significantly better to therapy than p53 null tu-
p53. CTX, like many other conventional anticancer agents, causes
mors (Figure 1). These ctrl.HSC-bcl2 tumors do not prolif-DNA damage which activates p53 through an ARF-independent
erate and express high p53 levels following therapy;mechanism. Block of p53-dependent and -independent apoptotic
by contrast, p53 null tumors (irrespective of their Bcl2pathways by Bcl2 uncovers senescence as a drug-induced re-
sponse program. Senescence is disrupted in the context of p53 or status) rapidly progress to a terminal stage. Therefore,
INK4a/ARF loss, whereas ARF deficiency alone is not sufficient the impact of p53 on drug action reflects the combined
to disable senescence. p16INK4a, like p53, can be induced by DNA effects of apoptosis and cellular senescence. Yet other
damaging treatment and probably cooperates with p53 in a common
p53 functions may contribute to drug action in somearrest program.
settings (Bearss et al., 2000; Bunz et al., 1999).
Loss of p53 function also accelerates tumorigenesis.
We recently demonstrated that apoptosis is the only
p53 effector function that suppresses myc-induced lym-
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phomagenesis (Schmitt et al., 2002). Hence, Bcl2 over- bination with ARF) have no additional impact (see Sherr,
2001b and Supplemental Data at above URL). Neverthe-expression in progenitor cells produces lymphomas that
are phenotypically identical to p53 mutant tumors but less, owing to their proximity,25% of E-myc lympho-
mas acquire spontaneous mutations that disable bothretain functional p53. Nevertheless, the p53 mutant tu-
mors, but not those overexpressing Bcl2, display check- genes—here, INK4a loss is a byproduct of ARF muta-
tions. This proximity also allows mutations targeting onepoint defects and aneuploidy, implying that these prop-
erties are byproducts of p53 loss. As shown here, gene (ARF) during tumor development to facilitate loss
of the other gene (INK4a) under therapy (Figure 4).another of these byproducts—defects in cellular senes-
cence—supplies an additional capability to a tumor that Hence, the precise way in which ARF is mutated during
lymphomagenesis has a profound impact on treatmentis revealed only under therapy. This capability is not
conferred to control E-myc lymphomas overexpress- outcome—mice harboring tumors that have disrupted
both genes have a worse prognosis than those withing Bcl2, despite their equally aggressive pre-treatment
behavior. Similarly, ARF loss completely disables p53 tumors lacking ARF alone.
during lymphomagenesis, yet allows p53 activation dur-
ing therapy (see Figure 7C). Consequently, ARF null tu- Mouse Models as Test Systems to Study
mors respond better to chemotherapy than p53 null tu- Drug Action
mors (Figures 1 and 3). Therefore, the precise way in The E-myc model provides a unique setting to study
which the p53 pathway is disabled during tumorigenesis drug action (Schmitt et al., 2000a). In this study, we
can give rise to heterogeneity in treatment responses. introduced transgenes into hematopoietic stem cells
from different genetic backgrounds to rapidly produce
tumors with compound genetic lesions, and tagged lym-INK4a/ARF Locus and Cancer Therapy
phoma cells with GFP to monitor treatment responsesOur data provide the first demonstration that p16INK4a
in vivo by fluorescence imaging. These approaches al-contributes to treatment outcome in vivo, and imply that
lowed us to dissect the biologic and genetic determi-this reflects its pro-senescence activity. First, tumors
nants of drug action in a manner that would be impossi-with engineered or spontaneous mutations disrupting
ble using cell lines or in patients. For example, thisboth INK4a and ARF are less responsive than those
system allowed us to spatially and temporally monitorharboring ARF mutations alone (Figures 3 and 4). Sec-
drug responses of individual primary lymphomas in theond, ARF null tumors often acquire INK4a deletions upon
presence of different genetic lesions, and to study po-tumor relapse, and antisense INK4a-exon 1
 can pre-
tential gene losses in untreated versus treated micevent treatment-induced INK4a loss (Figure 4). Third, cy-
harboring the same malignancy.tostatic tumors retaining INK4a and overexpressing Bcl2
While differences between mice and humans un-display high levels of p16INK4a post-therapy (Figures 5).
doubtedly exist, we believe that mouse models haveFinally, ARF null tumors retaining INK4a have elevated
enormous potential for evaluating drug action and pre-SA--gal activity post-therapy while INK4a/ARF null tu-
dicting treatment responses. Accordingly, much likemors do not (Figure 7). Still, while the evidence for
mice harboring ctrl.HSC-bcl2 lymphomas, chemotherapyp16INK4a involvement in treatment responses is compel-
achieves prolonged disease control in patients harbor-ling, it does not rule out a role for ARF in some settings
ing Bcl2 overexpressing follicular lymphomas, yet these(see Supplemental Data available online at http://www.
patients eventually enter a progressive clinical coursecell.com/cgi/content/full/109/3/335/DC1). As p16INK4a is
that is associated with acquired p53 or INK4a/ARF muta-more strongly associated with senescence in human
tions (Elenitoba-Johnson et al., 1998; Sander et al.,cells (Sherr and DePinho, 2000), the senescence pro-
1993). Similarly, INK4a lesions correlate with relapsesgram it controls may be even more important for drug
in Non-Hodgkin’s lymphomas that lacked INK4a abnor-action in patients.
malities at diagnosis (Maloney et al., 1999).p16INK4a probably promotes senescence by regulating
the Rb pathway. In fact, E-myc lymphomas arising in
Rb/ mice respond more poorly than ctrl. lymphomas Links between Cancer Genetics
and Cancer Therapy(C.A.S. and S.W.L., unpublished). However, in E-myc
lymphomas, p16INK4a action also depends on the pres- The fact that anticancer agents can rely on pathways
that naturally suppress tumorigenesis provides a linkence of wild-type p53. p53 null tumors proliferate de-
spite high levels of endogenous p16INK4a, and enforced between cancer genetics and cancer therapy (John-
stone et al., 2002). For example, apoptosis reveals ap16INK4a expression has little anti-proliferative effect (Fig-
ures 5 and 6; see also Bardeesy et al., 2001). It is unlikely brake against tumor development and contributes to
the action of anticancer agents; hence, disruption ofthat p16INK4a induces cell-cycle arrest through the p53
pathway; rather, we suspect that these molecules coop- apoptosis during tumor development can simultane-
ously select for drug resistant cells (Schmitt et al., 1999).erate such that intact p53 function makes the cell per-
missive for the p16INK4a effect (Figure 7C). Interestingly, This observation provides one explanation for intrinsic
drug resistance—i.e., resistance with no preceding drugp53 initiates, but does not maintain, senescence in mu-
rine fibroblasts (Ferbeyre et al., 2002), and it is possible exposure. In this study, we identify an unexpected twist
to this relationship. We see that byproducts of tumorthat p16INK4a contributes to the maintenance process.
The way in which the INK4a/ARF locus is mutated development—i.e., genetic changes not selected for
during tumor evolution—can give rise to acquired capa-during tumor development produces heterogeneity in
treatment responses. ARF mutations promote lympho- bilities that become relevant only under therapy. This
may be because the different components of the tumormagenesis, whereas INK4a mutations (alone or in com-
Drug-Induced Senescence In Vivo
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Monitoring Treatment Responses In Situ and Ex Vivosuppressor network play distinct roles during tumor de-
Measurement of apoptosis in situ and ex vivo was as describedvelopment and therapy (e.g., p53), or because the physi-
(Schmitt et al., 1999). For analysis of cell proliferation in vivo, primarycal arrangement of certain genes increases the probabil-
lymphomas were retransplanted into several animals each. Upon
ity that some mutations occur together (e.g., INK4a/ARF lymphoma formation, one tumor-bearing animal was left untreated
locus). In either case, this gives rise to heterogeneity in while the others received CTX, and the tumors were resected 7 days
later. In some cases, 5-bromo-2-deoxyuridine (BrdU, 100 mg/kgtreatment responses that ultimately translate into differ-
supplemented with 5-fluoro-2-deoxyuridine) was intraperitoneallyent prognoses.
administered 6 hr before lymphomas were harvested. BrdU wasThe E-myc model is remarkably simple. Each tumor
subsequently detected in paraffin-embedded 7 m sections usinganalyzed was initiated by the same oncogene (myc),
an anti-BrdU antibody (Amersham Pharmacia Biotech). Ki-67 and
arose in the same strain (C57BL/6), and was treated with BrdU were detected by immunohistochemistry using specific anti-
the same drug (CTX). Yet, these tumors displayed an bodies (anti-Ki67 [Dianova, Germany], 1:50 dilution; ImmunoCruz
anti-p16INK4a system, Santa Cruz). SA--gal activity was assessedextraordinary heterogeneity in treatment responses,
as described (Dimri et al., 1995) in 12 m cryosections derived fromranging from cure to progression under therapy de-
treated and untreated animals. Staining was for 12–16 hr at 37C.pending on their genotype. Given the complexities of
human oncology, it is no wonder that treatment re-
Immunoblotting and Immunoprecipitations
sponses are remarkably variable and difficult to predict. Immunoblotting was carried out using antibodies directed against
Undoubtedly this inherent variability will remain a prob- p53 (CM5, Novocastra, 1:2000 dilution), Bcl2 (13456E, PharMingen,
lem, even as we enter the age of targeted therapeutics. 1:750), ARF (NB200-106, Novus, 1:1000), p16INK4a (M-156, Santa Cruz,
1:500), and 
-Tubulin (B-5-1-2, Sigma, 1:2000) as a loading controlStill, our study provides a new paradigm to understand
(Schmitt et al., 1999). For p16INK4a immunoprecipitation, 500 g ofdrug action and inherent variations in treatment sensitiv-
protein lysates were incubated with a 1:40 dilution of M-156 at 4City, and provides support for the view that tumor geno-
for 3 hr. Immunoprecipitation/immunoblotting was carried out as
type is the most important determinant of treatment described using a 15%-SDS-polyacrylamide gel followed by immu-
outcome. These principles, when applied to human tu- noblotting with M-156 (de Stanchina et al., 1998).
mors, provide a strong rationale for individualized can-
Mutational Analysiscer therapy based on knowledge of drug action and
Loss of heterozygosity (LOH) at the p53 locus was detected bytumor genotype.
allele-specific PCR (Schmitt et al., 1999). Mutational analysis of the
p53 gene was carried out using RT-PCR products as described
Experimental Procedures (Schmitt et al., 1999). Gross deletions of the INK4a/ARF locus were
detected by multiplex PCR analysis of genomic DNA using exon-
Generation of Genetically Defined Lymphomas specific primers for exons 1
, 1, and 2 as well as for neomycin and
Lymphomas harboring loss-of-function lesions were produced by 
-actin as controls. Primer sequences and exact PCR conditions are
intercrossing E-myc transgenic mice with p53/, ARF/ available upon request. Southern blots were performed using equal
(	exon1), or INK4a/ARF/ (	exon2/3) mice, all in the C57BL/6 aliquots (10 g) of BamHI-digested lymphoma DNA samples that
background. Genotype and tumor onset were monitored as de- were separated on a 0.7% agarose gel and blotted onto a nylon
scribed (Schmitt et al., 1999). Lymphomas were resected from tu- membrane. After hybridization with a 32P-labeled exon 2 probe, spe-
mor-bearing mice and either snap frozen, formalin fixed, or pro- cific signals were scanned and quantified using NIH image 1.61
cessed to single cell suspensions and transplanted into syngeneic software.
recipient mice (Schmitt et al., 1999), or placed in short-term culture
for retroviral infection. Introduction of dominant activities into estab- Acknowledgments
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